Tag: Biotechnologies

AstraZeneca Bolsters Cell Therapy Pipeline With Over $1B Deal For China-Based Gracell Biotechnologies

AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire Gracell Biotechnologies Inc (NASDAQ: GRCL), further strengthening AstraZeneca’s cell therapy portfolio. The deal value is $2.00/share (equivalent to $10/ADS ADS of Gracell) plus a non-tradable contingent value right of $0.30/share (equivalent to $1.50/ADS of Gracell) in cash. The proposed acquisition will enrich AstraZeneca’s growing pipeline of cell therapies with GC012F, a […]

UPDATE 1-AstraZeneca to buy China-based Gracell Biotechnologies in $1.2 bln deal

(Adds details in paragraphs 2-6) Dec 26 (Reuters) – AstraZeneca said on Tuesday it will buy China-based Gracell Biotechnologies for up to $1.2 billion as the British pharma company furthers its cell therapy ambitions. The cash deal aimed at bolstering AstraZeneca’s portfolio values U.S.-listed Gracell at $2 per ordinary share or $10 per ADS of […]